UIC202201

**UIC202201** is a Korea United Pharm oral fixed-dose combination product containing **rabeprazole** and **sodium bicarbonate**, being evaluated in Phase 1 crossover pharmacokinetic and pharmacodynamic studies in healthy adults in the context of gastroesophageal reflux disease development. Rabeprazole is a proton-pump inhibitor that irreversibly suppresses gastric acid secretion through inhibition of gastric hydrogen-potassium ATPase, while sodium bicarbonate rapidly elevates intragastric pH, helps protect the acid-labile PPI from degradation, and supports more rapid absorption. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06141577))

Other names

UIC 202201UIC202201UIC-202201